ArticleTheranostics2021

The Polo-like kinase 1 inhibitor onvansertib represents a relevant treatment for head and neck squamous cell carcinoma resistant to cisplatin and radiotherapy.

Anais Hagege et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.